Affimed’s main strengths were its differentiated scientific focus, proprietary platforms for engaging the innate immune system, and promising clinical data—especially for its lead innate cell engager in combination with NK‑cell therapies. Historically, it also benefited from a relatively clean balance sheet with limited fixed assets and strong early‑stage cash positions, as well as validation from high‑quality partners. Operationally, low capital expenditure needs meant that most resources could be directed toward R&D innovation rather than heavy infrastructure.

The risks surrounding Affimed proved to be substantial. Persistent and widening losses, increasingly negative cash flows, and heavy dependence on external financing created a fragile financial structure. Volatile collaboration revenues, lack of approved products, and the long, uncertain path of oncology drug development all amplified this fragility. These pressures ultimately led to insolvency, delisting, and a highly uncertain outcome for existing equity holders, underscoring the extreme financial and execution risks inherent in small clinical‑stage biotech companies.

Looking ahead, the outlook for Affimed as an independent, publicly traded entity is effectively closed, given its insolvency and removal from Nasdaq. However, the outlook for its underlying science and assets is more nuanced: the technology platforms, lead programs, and clinical data may attract acquirers or licensees who can provide the capital and infrastructure needed to advance them. The eventual value realization, if any, will depend on how the assets are handled in restructuring or sale processes and on the continued clinical and regulatory success of the programs under new stewardship.